Metropolis Healthcare Ltd

Metropolis Healt Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Metropolis Healthcare Ltd

₹ 529 -2.19%
15 May - close price
metropolisindia.com BSE: 542650 NSE: METROPOLIS
About

Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.

Key Points

Leading Diagnostics company[1] Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India.

Website BSE NSE
  • Market Cap ₹ 10,965 Cr.
  • Current Price ₹ 529
  • High / Low ₹ 600 / 400
  • Stock P/E 67.3
  • Book Value ₹ 64.0
  • Dividend Yield 0.38 %
  • ROCE 16.8 %
  • ROE 13.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 8.26 times its book value
  • The company has delivered a poor sales growth of 10.8% over past five years.
  • Company has a low return on equity of 11.8% over last 3 years.
  • Dividend payout has been low at 5.90% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE 500 BSE Healthcare BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty Microcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
264 256 285 269 292 286 322 297 312 324 356 335 352
197 198 218 211 218 218 240 232 259 247 264 255 262
Operating Profit 68 58 67 59 74 68 82 65 53 77 91 80 90
OPM % 26% 23% 24% 22% 25% 24% 26% 22% 17% 24% 26% 24% 26%
9 3 2 5 2 3 4 3 8 3 3 -6 9
Interest 6 6 6 5 6 5 5 4 4 4 4 4 7
Depreciation 22 20 21 24 25 25 26 27 27 28 28 28 33
Profit before tax 48 35 42 35 45 42 55 37 29 48 62 42 60
Tax % 17% 26% 26% 23% 29% 25% 23% 26% 17% 25% 25% 24% 27%
40 26 31 27 32 31 42 27 24 36 47 32 43
EPS in Rs 1.95 1.28 1.53 1.30 1.55 1.53 2.06 1.34 1.15 1.72 2.25 1.55 2.09
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
254 349 405 485 581 665 816 1,157 1,066 1,103 1,217 1,365
183 263 289 348 434 489 574 833 792 840 944 1,027
Operating Profit 71 86 115 137 148 176 242 324 274 263 273 338
OPM % 28% 25% 29% 28% 25% 26% 30% 28% 26% 24% 22% 25%
6 39 30 15 20 5 49 32 21 12 17 9
Interest 2 1 2 3 3 10 9 25 31 27 23 19
Depreciation 10 12 12 14 15 31 36 60 85 91 105 116
Profit before tax 65 112 131 135 149 140 246 272 179 157 162 212
Tax % 33% 32% 33% 29% 32% 20% 20% 27% 22% 26% 23% 26%
43 76 88 96 101 112 198 200 139 116 125 157
EPS in Rs 10.90 19.88 23.04 25.07 5.06 5.53 9.66 9.75 6.78 5.66 6.02 7.60
Dividend Payout % 0% 101% 57% 0% 66% 36% 21% 21% 29% 18% 0% 0%
Compounded Sales Growth
10 Years: 15%
5 Years: 11%
3 Years: 9%
TTM: 12%
Compounded Profit Growth
10 Years: 9%
5 Years: -4%
3 Years: 5%
TTM: 36%
Stock Price CAGR
10 Years: %
5 Years: -2%
3 Years: 18%
1 Year: 28%
Return on Equity
10 Years: 19%
5 Years: 14%
3 Years: 12%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 10 10 10 10 10 10 10 10 10 10 10 10
Reserves 296 233 258 354 405 502 699 829 926 1,021 1,234 1,317
10 4 0 0 17 54 85 377 268 195 178 152
35 95 170 76 95 122 140 242 230 247 262 252
Total Liabilities 351 341 438 440 528 688 933 1,459 1,434 1,473 1,685 1,732
84 92 152 157 163 216 251 1,005 1,066 1,120 1,129 1,110
CWIP 0 0 0 0 6 3 0 6 20 0 0 0
Investments 175 120 143 98 135 130 131 50 50 90 321 362
92 129 143 185 224 340 552 398 299 263 235 259
Total Assets 351 341 438 440 528 688 933 1,459 1,434 1,473 1,685 1,732

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
43 75 77 74 56 156 202 244 238 269 275 318
-36 101 -67 19 -4 -51 74 -736 47 -82 -196 -209
-10 -165 -17 -82 -64 -46 -26 172 -288 -183 -84 -111
Net Cash Flow -3 11 -6 12 -12 59 250 -320 -3 4 -6 -2
Free Cash Flow 30 65 65 59 37 133 178 207 189 209 213 288
CFO/OP 91% 122% 100% 88% 73% 116% 103% 99% 103% 112% 113% 103%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 60 50 56 62 74 68 55 44 43 43 34
Inventory Days 50 42 35 49 52 38 57 66 64 56 47
Days Payable 71 84 93 87 95 155 155 131 133 155 160
Cash Conversion Cycle 38 7 -1 24 31 -48 -42 -22 -26 -55 -79
Working Capital Days 48 12 -47 43 47 20 10 -20 -15 -15 -24
ROCE % 22% 37% 50% 43% 38% 35% 37% 28% 17% 15% 13%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Clinical Laboratories
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Patient Visits (Millions)
Millions
Number of Tests Conducted (Millions)
Millions
Service Network points (Collection Centers/PSCs/ARCs)
Number
Revenue Per Patient (RPP)
INR

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
49.75% 49.75% 49.74% 49.67% 49.62% 49.43% 49.40% 48.89% 48.89% 48.89% 48.87% 48.86%
25.66% 24.29% 21.66% 18.90% 18.25% 18.56% 16.73% 15.29% 12.83% 12.52% 11.68% 10.43%
14.89% 16.86% 20.73% 24.86% 27.42% 28.02% 30.00% 30.30% 32.40% 33.10% 34.73% 35.80%
9.69% 9.10% 7.87% 6.57% 4.69% 3.98% 3.86% 5.51% 5.87% 5.48% 4.69% 4.92%
No. of Shareholders 89,69286,24979,87868,28358,10851,85248,57249,29350,01547,84646,67049,175

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls